Paolo A Ascierto


Ontology type: schema:Person     


Person Info

NAME

Paolo A

SURNAME

Ascierto

Publications in SciGraph latest 50 shown

  • 2018-12 The influence of diet on anti-cancer immune responsiveness in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2018-12 The Great Debate at “Melanoma Bridge”, Napoli, December 2nd, 2017 in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2018-12 Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November–2 December, 2017, Naples, Italy) in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2018-09-25 Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma in CELL DEATH & DIFFERENTIATION
  • 2018-03-20 Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation–positive melanoma in BRITISH JOURNAL OF CANCER
  • 2017-12 Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy? in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2017-12 Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2017-12 Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2017-09 FKBP51s signature in peripheral blood mononuclear cells of melanoma patients as a possible predictive factor for immunotherapy in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2016-12 Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, December 5th 2015 in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2016-09 Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2016-06 Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection? in DRUGS
  • 2015-12 The immune-related role of BRAF in melanoma in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2015-12 Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2015-12 Correlation between BRAF mutational status and clinical response to pembrolizumab in advanced melanoma patients in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2015-12 AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2015-12 Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2015-12 coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519) in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2015-12 A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2015-12 Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2014-12 Melanoma: the role of surgery in the era of new therapies in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2014-12 Immunoscore: a new possible approach for melanoma classification in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2014-12 Tomotherapy concomitant with cetuximab, followed by cetuximab as single-agent therapy for unresectable squamous cell carcinoma of the skin: a case report in BMC DERMATOLOGY
  • 2014-12 Highlights and summary of the 28th annual meeting of the Society for Immunotherapy of Cancer in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2014-12 What have we learned from cancer immunotherapy in the last 3 years? in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2014-11 Erratum to: Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2014-05 MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2014-05 Efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2014-05 Assessment of germline and somatic alterations in main candidate genes among patients with multiple primary melanoma in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2014-04 Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy in BRITISH JOURNAL OF CANCER
  • 2013-12 Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012” in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2013-12 Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5–7, 2012 in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2013-12 Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2013-12 Do BRAF inhibitors select for populations with different disease progression kinetics? in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2013-12 The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2013-12 Effect of dabrafenib on melanoma cell lines harbouring the BRAFV600D/Rmutations in BMC CANCER
  • 2013-12 Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme in JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
  • 2013-12 Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2013-12 Superficial and deep lymph node dissection for stage III cutaneous melanoma: clinical outcome and prognostic factors in WORLD JOURNAL OF SURGICAL ONCOLOGY
  • 2013-11 Genomic scale analysis of NK cells impact on response to IFN-α in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2013-06 Mutations in ERBB4 May Have a Minor Role in Melanoma Pathogenesis in JOURNAL OF INVESTIGATIVE DERMATOLOGY
  • 2013-03 Molecular detection and targeting of EWSR1 fusion transcripts in soft tissue tumors in MEDICAL ONCOLOGY
  • 2013 Therapeutic Targeting of the Bone Pre-metastatic Niche in PROSTATE CANCER: SHIFTING FROM MORPHOLOGY TO BIOLOGY
  • 2013 Targeting Tumor Angiogenesis in PROSTATE CANCER: SHIFTING FROM MORPHOLOGY TO BIOLOGY
  • 2012-12 Cancer classification using the Immunoscore: a worldwide task force in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2012-12 Increased HOX C13 expression in metastatic melanoma progression in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2012-12 The role of BRAF V600 mutation in melanoma in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2012-12 FUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the “Melanoma Research: a bridge from Naples to the World. Napoli, December 5th–6 th2011” in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2012-12 The immune score as a new possible approach for the classification of cancer in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2012-12 Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report in JOURNAL OF MEDICAL CASE REPORTS
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "https://www.grid.ac/institutes/grid.417893.0", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.266539.d", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.257413.6", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.484420.e", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.48336.3a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.419457.a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.5606.5", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.10306.34", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.240145.6", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.476273.3", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.25879.31", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.11450.31", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.419690.3", 
            "type": "Organization"
          }
        ], 
        "familyName": "Ascierto", 
        "givenName": "Paolo A", 
        "id": "sg:person.01212502023.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01212502023.44"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2019-03-07T14:54", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-researchers-20181010/20181011/dim_researchers/base/researchers_621.json", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.01212502023.44'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.01212502023.44'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.01212502023.44'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.01212502023.44'


     

    This table displays all metadata directly associated to this object as RDF triples.

    40 TRIPLES      10 PREDICATES      23 URIs      7 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:person.01212502023.44 schema:affiliation Nce35f48cb56e40ca89ef6f8bef107adf
    2 https://www.grid.ac/institutes/grid.10306.34
    3 https://www.grid.ac/institutes/grid.11450.31
    4 https://www.grid.ac/institutes/grid.240145.6
    5 https://www.grid.ac/institutes/grid.257413.6
    6 https://www.grid.ac/institutes/grid.25879.31
    7 https://www.grid.ac/institutes/grid.266539.d
    8 https://www.grid.ac/institutes/grid.419457.a
    9 https://www.grid.ac/institutes/grid.419690.3
    10 https://www.grid.ac/institutes/grid.476273.3
    11 https://www.grid.ac/institutes/grid.48336.3a
    12 https://www.grid.ac/institutes/grid.484420.e
    13 https://www.grid.ac/institutes/grid.5606.5
    14 schema:familyName Ascierto
    15 schema:givenName Paolo A
    16 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01212502023.44
    17 schema:sdDatePublished 2019-03-07T14:54
    18 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    19 schema:sdPublisher N0d1acab156044eb29a99d8977016a15a
    20 sgo:license sg:explorer/license/
    21 sgo:sdDataset persons
    22 rdf:type schema:Person
    23 N0d1acab156044eb29a99d8977016a15a schema:name Springer Nature - SN SciGraph project
    24 rdf:type schema:Organization
    25 Nce35f48cb56e40ca89ef6f8bef107adf schema:affiliation https://www.grid.ac/institutes/grid.417893.0
    26 sgo:isCurrent true
    27 rdf:type schema:OrganizationRole
    28 https://www.grid.ac/institutes/grid.10306.34 schema:Organization
    29 https://www.grid.ac/institutes/grid.11450.31 schema:Organization
    30 https://www.grid.ac/institutes/grid.240145.6 schema:Organization
    31 https://www.grid.ac/institutes/grid.257413.6 schema:Organization
    32 https://www.grid.ac/institutes/grid.25879.31 schema:Organization
    33 https://www.grid.ac/institutes/grid.266539.d schema:Organization
    34 https://www.grid.ac/institutes/grid.417893.0 schema:Organization
    35 https://www.grid.ac/institutes/grid.419457.a schema:Organization
    36 https://www.grid.ac/institutes/grid.419690.3 schema:Organization
    37 https://www.grid.ac/institutes/grid.476273.3 schema:Organization
    38 https://www.grid.ac/institutes/grid.48336.3a schema:Organization
    39 https://www.grid.ac/institutes/grid.484420.e schema:Organization
    40 https://www.grid.ac/institutes/grid.5606.5 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...